Nevro Acquisition Finalized as Trading Ceases on NYSE

A $250 Million Transaction Seals the Deal

The independent public trading journey of Nevro has reached its conclusion. Effective April 3, 2025, the company’s shares are no longer listed on the New York Stock Exchange, following its complete acquisition by Globus Medical.

The acquisition process, which was initially announced in February 2025, was finalized this April. The transaction saw Globus Medical disburse approximately $250 million in cash and assume all of Nevro’s outstanding shares. Shareholders received $5.85 for each share they held. The agreement received unanimous approval from the boards of directors of both corporations.